ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

RO7663498

A development code.

Its studies are mostly in Diabetic Retinopathy, led by Hoffmann-La Roche.

Furthest: phase 1, since May 8, 20261 company-led study, 1 open or runningNext primary completion: Jan 20, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche11 open or runningphase 1since May 8, 2026May 8, 2026Jan 20, 2028phase 1 · NCT07588100

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 8, 2026First study: phase 1 study in Diabetic RetinopathyFirst studyNCT07588100 · 30 planned · United States

Ahead

  1. Jan 20, 2028Primary completion: phase 1 study in Diabetic RetinopathyNCT07588100

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07588100Diabetic Retinopathy · United States1RecruitingJan 20, 202830

How it is read

Names in the registry

  • “RO7663498”, 1 entry

Codes read as this program: RO7663498.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.